Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors.

ABSTRACT: Development of selective kinase inhibitors remains a challenge due to considerable amino acid sequence similarity among family members particularly in the ATP binding site. Targeting the activation loop might offer improved inhibitor selectivity since this region of kinases is less conserved. However, the strategy presents difficulties due to activation loop flexibility. Herein, we report the design of receptor-interacting protein kinase 2 (RIPK2) inhibitors based on pan-kinase inhibitor regorafenib that aim to engage basic activation loop residues Lys169 or Arg171. We report development of CSR35 that displayed >10-fold selective inhibition of RIPK2 versus VEGFR2, the target of regorafenib. A co-crystal structure of CSR35 with RIPK2 revealed a resolved activation loop with an ionic interac

SUBMITTER: Suebsuwong C 

PROVIDER: S-EPMC5819902 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature